Leg, Foot Amputations Linked To Invokana Being Investigated By FDA, Europe

(May 20, 2016, 10:45 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on May 18 said it is investigating interim safety results from an ongoing clinical trial that found an increase in leg and foot amputation in patients treated with the diabetes drug Invokana.

The FDA said the interim safety results are from the Canagliflozin Cardiovascular Assessment Study (CANVAS) clinical trial. It said the trial’s independent data-monitoring committee identified the increased risk of leg and foot amputations.

“The amputations occurred about twice as often in patients treated with canagliflozin...
To view the full article, register now.